Model 1 | Model 2 | Model 3 | ||||
---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
Sex (vs. female) | 0.658 (0.189 – 2.292) | 0.511 | 0.821 (0.215 – 3.132) | 0.773 | 0.741 (0.175 – 3.149) | 0.685 |
Age (per 1 year increase) | 0.952 (0.914 – 0.992) | 0.020 | 0.950 (0.911 – 0.991) | 0.017 | 0.945 (0.902 – 0.991) | 0.019 |
HTN (vs. no) | 0.675 (0.184 – 2.476) | 0.553 | 0.793 (0.194 – 3.242) | 0.746 | 0.663 (0.138 – 3.198) | 0.609 |
TAP (per 1 g/g increase) | 1.887 (1.399 – 2.546) | <0.001 | 1.881 (1.392 – 2.543) | <0.001 | 1.979 (1.382 – 2.832) | <0.001 |
eGFR (per 1 ml/min/1.73 m2 increase) | 0.955 (0.932 – 0.979) | <0.001 | 0.951 (0.923 – 0.978) | 0.001 | 0.952 (0.926 – 0.978) | <0.001 |
Pathologic variants | ||||||
NOS | – | – | Reference | Reference | ||
Perihilar | – | – | 1.054 (0.189 – 5.862) | 0.952 | 1.019 (0.183 – 5.664) | 0.983 |
Tip | – | – | 1.699 (0.160 – 18.052) | 0.660 | 1.657 (0.162 – 16.949) | 0.670 |
Immunosuppression (vs. no) | – | – | 0.622 (0.120 – 3.225) | 0.572 |